Bartkoski Michael, Poweleit Ethan A, Stancil Stephani L
Division of Clinical Pharmacology, Toxicology, & Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Clin Transl Sci. 2025 Jun;18(6):e70262. doi: 10.1111/cts.70262.
Glucagon-like peptide-1 agonists (GLP-1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents. Emerging evidence suggesting neuropsychiatric effects presents an opportunity for pediatric psychopharmacology but requires careful consideration of potential adverse effects and risk of misuse. This perspective examines potential applications and cautions surrounding GLP-1As for pediatric mental health, particularly substance use, depression, and eating disorders, and advocates for research and clinical monitoring to ensure their safety and efficacy.
胰高血糖素样肽-1激动剂（GLP-1A）越来越多地被用于治疗儿童和青少年的肥胖症及2型糖尿病。新出现的证据表明其具有神经精神方面的影响，这为儿科精神药理学带来了机遇，但需要仔细考虑潜在的不良反应和滥用风险。本文观点探讨了GLP-1A在儿童心理健康方面的潜在应用及注意事项，特别是在物质使用、抑郁症和饮食失调方面，并倡导进行研究和临床监测以确保其安全性和有效性。
